A drug discovery and development company uniquely focused on the therapeutic potential of cannabinoids
InMed Pharmaceuticals, Inc. (OTCQB: (IMLFF; CSE: IN) is a preclinical-stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems. InMed conducts research, discovery, pre-clinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. The three core asset groups of the Company, namely, the bioinformatics database assessment tool, the biosynthesis manufacturing process, and the drug development programs serves as InMed's fundamental value drivers.
InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents while developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of $1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.
- Extensive portfolio of assets in dermatology, ocular disease and additional indications and cannabinoid biosynthesis
Positioned to achieve value-driving, near-term corporate milestones with limited investment
Led by a management team of experienced professionals capable of building value in biopharmaceuticals
Bioinformatics: a significant promise for future drug discovery
Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis.
With this tool, InMed aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases.
After discovering active cannabinoids, InMed tests and confirms their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company's proprietary biosynthesis process of cannabinoid manufacturing will be most promising.
InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.
InMed is building a robust product pipeline through its proprietary discovery platform and research & product development programs. The company continues to seek innovative product candidates for the treatment in following therapeutic areas:
- Ocular Diseases
Pain & Inflammation
InMed's pipeline currently includes two drug candidates in preclinical development: INM-750 for the treatment of epidermolysis bullosa (EB); and INM-085 for the treatment of glaucoma.
Referred to as "The Worst Disease You've Never Heard Of," EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States.
INM-750 is a proprietary, topical cannabinoid product candidate intended as a dual approach therapy that may prove beneficial to patients in two ways: first, the ability of certain cannabinoids to play a role in addressing key disease hallmarks (wound healing, infection, pain, itch, inflammation); and second, the ability of some cannabinoids to regulate the expression of various proteins incriminated in EB's pathogenesis by upregulating certain keratins in the skin in an effort to modulate the painful manifestations of EB.
Through the development of INM-750, InMed's lead program, InMed is attempting to address this significant unmet medical need, in this Orphan indication, for which there is no approved treatment or cure.
Market Potential - Amicus Therapeutics recently acquired Scioderm, Inc. and its lead EB drug candidate, Zorblisa™, for $847 million. Notably, Scioderm's sole clinical asset was Zorblisa.
JP Morgan and Cowen Research Reports estimate that peak sales for Zorblisa could reach $900 million to $1.2 billion.
INM-085 is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration of this dual action approach to treatment. Additionally, InMed is developing a proprietary once-a day hydro-gel, an important drug delivery technology for this therapy. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure.
Market Potential - The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease. Worldwide, glaucoma represents a market of $5.6 billion.
The Case for Cannabinoids
The majority of pharmaceutical and academic research & development activities being performed with cannabis revolves around the understanding of its biologically active ingredients, the cannabinoids.
Currently there are 90+ cannabinoids that have been isolated from cannabis, each affecting the body's cannabinoid receptors and responsible for unique pharmacological effects. There are currently two known types of cannabinoid receptors, called CB1 and CB2.
CB1 receptors are primarily found in the brain and central nervous system, and to a lesser extent in other issues.
CB2 receptors are mostly in the peripheral organs, especially cells associated with the immune system.
Cannabinoids can be administered by smoking, vaporizing, oral ingestion, transdermal patch, intravenous injection, sublingual absorption, or rectal suppository. Once in the body, most cannabinoids are metabolized in the liver, although some is stored in fat.
Cannabinoids can be separated from the plant by extraction with organic solvents. However, to produce high purity, cannabinoid chemical synthesis or semisynthesis is generally required.
InMed specializes in developing novel therapies through the R&D into the extensive pharmacology of cannabinoids in combination with innovative drug delivery systems, positioning the company as a unique first-mover in the cannabis-pharma sector.
InMed's management team and board of directors have well over a century of combined experience in the biopharmaceutical space. Together, the professionals comprising this team are guiding InMed into exciting opportunities in the cannabis-pharma sector.
Eric A. Adams, President & CEO
Eric Adams is a seasoned biopharmaceutical executive with over 25 years of experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada's Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs.
He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana aerospace industry, most recently with Metal Form, Inc., a privately held aerospace manufacturing company, where he served as president and CEO from 1987 to September of 1999.
Dr. Sazzad Hossain, Ph.D., M.Sc., Chief Scientific Officer
Dr. Sazzad Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development. He was Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada's prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases. Prior to joining the National Research Council Canada, he was at Xenon Pharmaceuticals in Vancouver, B.C, where was Associate Director of Pharmacology and led pharmacology teams targeting pain, inflammation and cardiovascular diseases. Dr. Hossain received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of University of British Columbia. He was associate professor of pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996. He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.
Dr. Ado Muhammed, MD, DPM, MFPM, Chief Medical Officer
Dr. Ado Muhammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs. His previous position was Associate Medical Director at GW Pharmaceuticals, a UK-based Pharmaceutical Company specializing in the development of cannabinoid based prescription medicines. In this role and others at GW Pharmaceuticals, Dr. Muhammed was involved in the advanced delivery of core clinical research and was involved in key decision-making regarding R&D and product commercialization. Dr. Muhammed's received his MD at Ahmadu Bello University followed by an MSc in Orthopaedics at University College London. Dr. Muhammed achieved a DipPharMed in Pharmaceutical Medicine at University of Wales in Cardiff followed by an MBA in Business Administration at the University of Leicester. He is Member, Faculty of Pharmaceutical Medicine (Royal College of Physicians of England), the British Association of Pharmaceutical Physicians and the International Society for Pharmacovigilance.
Alexandra D.J. Mancini, M.Sc., Senior Vice President, Clinical and Regulatory Affairs
Alexandra Mancini has over 30 years of global biopharmaceutical R&D experience with a particular emphasis on clinical development and regulatory affairs. Mancini has been an executive with several biotech companies, overseeing a wide range of drug development activities. As Sr. VP of Clinical & Regulatory Affairs at Sirius Genomics, her role included identifying and managing external resources for medical expertise in sepsis; clinical data management; and statistical theory, programming and analyses. While at INEX Pharmaceuticals as Sr. VP of Clinical & Regulatory Affairs, Mancini oversaw Clinical Research, Medical Affairs, Clinical Data Management, Medical Writing, Regulatory Affairs, and Quality Assurance for oncology. She served as VP of Regulatory Affairs at QLT Inc. for oncology and ocular diseases, playing a significant role in the development of VISUDYNER from the preclinical stage through to its approval as the first drug for age-related macular degeneration. While at QLT, Mancini also led the regulatory approval process for the anticancer drug PHOTOFRINR and its associated medical devices, the first drug-device combination product approved by the US Food and Drug Administration. Mancini has led the data analysis and assimilation, writing, submission and subsequent defense of drug submissions to regulatory agencies around the world, leading to several drug approvals and label extensions. Mancini holds a Master of Science degree from the University of Toronto. She is also a Visiting Lecturer at the Segal Graduate School of Business, Simon Fraser University.
Martin Bott, Director
Martin Bott has over 28 years of experience in senior financial and executive leadership. He currently serves as VP of Corporate Finance and Investment Banking at Eli Lilly & Company. He joined Lilly in 1988 and has held roles of increasing responsibility at their headquarters in Indianapolis as well as affiliates in Switzerland, Germany, and the UK. Prior to his current assignment, Bott was the CFO for both the Diabetes Business and the Global Manufacturing and Quality organizations. He has been a member of the Lilly CFO Staff since December 2002. Bott has a Bachelor of Business / Marketing (Cologne, Germany, 1985) and a Master's in International Business Studies (University of South Carolina, 1988).
Andrew Hull, Director
Andrew Hull has over 30 years of experience in various commercial and business development roles with leading pharmaceutical and biotech companies. He currently serves as Vice President of Global Alliances for Takeda Pharmaceuticals where he is responsible for maximizing the success of Takeda's growing number (40+) of commercial and R&D partnerships with many of the industry's leading pharmaceutical and biotech companies. In previous roles, he led marketing and commercial development of Takeda's US portfolio of over $3 billion including diabetes, neuroscience, GI and cardiovascular therapies. Additionally, he held positions of increasing responsibility at Immunex and Abbott Labs. Hull received a bachelor's degree in biology from Kenyon College in 1985. He serves as a member of the Board of Directors of the Illinois Biotechnology Industry Organization and is a member of the Kenyon College Board of Trustees.
For a full listing of individuals on InMed's management team, Board of Directors and Scientific Advisory Board visit:
InMed Pharmaceuticals, Inc.
#350-409 Granville Street
Canada V6C 1T2
Phone: (604) 669-7207
1324 Lexington Ave.
New York, NY 10128
Phone: (212) 418-1217
NetworkNewsWire is a moderator of this board. Please see disclaimer on the NetworkNewsWire website: https://www.networknewswire.com/disclaimer/